Literature DB >> 26053366

The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data.

Candace Gunnarsson1, Jie Chen, John A Rizzo, Joseph A Ladapo, Ahmad Naim, Jennifer H Lofland.   

Abstract

OBJECTIVE: To estimate indirect costs associated with rheumatoid arthritis (RA).
METHODS: This was a retrospective study using 1996-2006 US Medical Expenditure Panel Survey data. Employed individuals were aged 18 to 65 years. A two-part model estimated the probability of time lost from work and annual number of workdays missed due to illness.
RESULTS: Sixty-seven percent (209/312) of RA individuals missed work versus 58% (52,046/89,734) of those without RA (P = 0.0007). Among individuals who missed work, those with RA missed more workdays annually than those without RA ((Equation is included in full-text article.)= 13.659, 9.879, respectively; P = 0.008). Incremental per capita costs in annual lost workdays between those with and without RA were $596. Estimated national indirect costs of RA-related absenteeism were $252 million annually.
CONCLUSIONS: Individuals with RA have higher probabilities of missing work and missing workdays than those without RA.

Entities:  

Mesh:

Year:  2015        PMID: 26053366     DOI: 10.1097/JOM.0000000000000461

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  8 in total

1.  Chronic Condition Combinations and Productivity Loss Among Employed Nonelderly Adults (18 to 64 Years).

Authors:  Abdulkarim M Meraya; Usha Sambamoorthi
Journal:  J Occup Environ Med       Date:  2016-10       Impact factor: 2.162

2.  A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia.

Authors:  Pedro Santos-Moreno; Nelson J Alvis-Zakzuk; Laura Villarreal-Peralta; Maria Carrasquilla-Sotomayor; Angel Paternina-Caicedo; Nelson Alvis-Guzmán
Journal:  Rheumatol Int       Date:  2017-12-16       Impact factor: 2.631

3.  New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study.

Authors:  Matthias Englbrecht; Rieke Alten; Martin Aringer; Christoph G Baerwald; Harald Burkhardt; Nancy Eby; Jan-Paul Flacke; Gerhard Fliedner; Ulf Henkemeier; Michael W Hofmann; Stefan Kleinert; Christian Kneitz; Klaus Krüger; Christoph Pohl; Georg Schett; Marc Schmalzing; Anne-Kathrin Tausche; Hans-Peter Tony; Jörg Wendler
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

Review 4.  Migration and homeostasis of regulatory T cells in rheumatoid arthritis.

Authors:  Konstantin Kotschenreuther; Shuaifeng Yan; David M Kofler
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

5.  A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update.

Authors:  Jessica Lo; Leighton Chan; Spencer Flynn
Journal:  Arch Phys Med Rehabil       Date:  2020-04-24       Impact factor: 3.966

6.  Early-life famine exposure and rheumatoid arthritis in Chinese adult populations: a retrospective cohort study.

Authors:  Chunyu Liu; Xiangrui Meng; Hao Zhang; Fan Yang; Xiaoyu Pan; Kun Tang
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

7.  Increased incidence of rheumatoid arthritis in multiple sclerosis: A nationwide cohort study.

Authors:  Chia-Chun Tseng; Shun-Jen Chang; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Ming-Chia Hsieh; Jeng-Hsien Yen
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

8.  Prevalence of Cancer in Rheumatoid Arthritis: Epidemiological Study Based on the National Health and Nutrition Examination Survey (NHANES).

Authors:  Binita Bhandari; Bikash Basyal; Manbeer S Sarao; Vinod Nookala; Yamin Thein
Journal:  Cureus       Date:  2020-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.